lyophilization comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
However, its toxicity to microorganisms is not overtly observed since the free silver ion is found in low concentrations in wastewater treatment systems and the natural environment due to its complexation with ligands such as chloride, sulfide, and thiosulfate.
==== MeSH D13.695.740 – pyrimidine nucleotides ==== MeSH D13.695.740.050 – apurinic acid MeSH D13.695.740.246 – cytosine nucleotides MeSH D13.695.740.246.050 – arabinofuranosylcytosine triphosphate MeSH D13.695.740.246.115 – cyclic cmp MeSH D13.695.740.246.150 – cytidine diphosphate MeSH D13.695.740.246.150.180 – cytidine diphosphate choline MeSH D13.695.740.246.150.210 – cytidine diphosphate diglycerides MeSH D13.695.740.246.370 – cytidine monophosphate MeSH D13.695.740.246.370.250 – cytidine monophosphate n-acetylneuraminic acid MeSH D13.695.740.246.400 – cytidine triphosphate MeSH D13.695.740.246.425 – deoxycytosine nucleotides MeSH D13.695.740.246.425.300 – deoxycytidine monophosphate MeSH D13.695.740.600 – pyrimidine dimers MeSH D13.695.740.706 – thymine nucleotides MeSH D13.695.740.706.788 – thymidine monophosphate MeSH D13.695.740.850 – uracil nucleotides MeSH D13.695.740.850.210 – deoxyuracil nucleotides MeSH D13.695.740.850.210.200 – fluorodeoxyuridylate MeSH D13.695.740.850.600 – uridine diphosphate MeSH D13.695.740.850.600.677 – uridine diphosphate sugars MeSH D13.695.740.850.600.677.100 – uridine diphosphate n-acetylgalactosamine MeSH D13.695.740.850.600.677.120 – uridine diphosphate n-acetylglucosamine MeSH D13.695.740.850.600.677.150 – uridine diphosphate n-acetylmuramic acid MeSH D13.695.740.850.600.677.300 – uridine diphosphate galactose MeSH D13.695.740.850.600.677.350 – uridine diphosphate glucose MeSH D13.695.740.850.600.677.375 – uridine diphosphate glucuronic acid MeSH D13.695.740.850.600.677.800 – uridine diphosphate xylose MeSH D13.695.740.850.877 – uridine monophosphate MeSH D13.695.740.850.877.500 – sofosbuvir MeSH D13.695.740.850.950 – uridine triphosphate
When measured by fatalities per person transported, however, buses are the safest form of transportation. The number of air travel fatalities per person are surpassed only by bicycles and motorcycles. This statistic is used by the insurance industry when calculating insurance rates for air travel. For every billion kilometers traveled, trains have a fatality rate that is 12 times higher than that of air travel, and the fatality rate for automobiles is 62 times greater than for air travel. By contrast, for every billion journeys taken, buses are the safest form of transportation; using this measure, air travel is three times more dangerous than car transportation, and almost 30 times more dangerous than travelling by bus. A 2007 study by Popular Mechanics magazine found that passengers sitting at the back of an aeroplane are 40% more likely to survive a crash than those sitting at the front. The article quotes Boeing, the FAA, and a website on aircraft safety, all of which claim that there is no "safest" seat. The study examined 20 crashes, not taking into account the developments in safety after those accidents. However, a flight data recorder is usually mounted in the aircraft's empennage (tail section) where it is more likely to survive a severe crash. Between 1983 and 2000, the survival rate for people in U.S. plane crashes was greater than 95 percent.
Moving forward, though, the potential for real biological computers is immense. We are essentially talking about fully-functional computers that can sense their surroundings, and then manipulate their host cells into doing just about anything. Biological computers might be used as an early-warning system for disease, or simply as a diagnostic tool ... Biological computers could tell their host cells to stop producing insulin, to pump out more adrenaline, to reproduce some healthy cells to combat disease, or to stop reproducing if cancer is detected. Biological computers will probably obviate the use of many pharmaceutical drugs. UC Berkeley biochemical engineer Jay Keasling said the transcriptor "clearly demonstrates the power of synthetic biology and could revolutionize how we compute in the future".
Sources: en.wikipedia.org
=== Phase 2 === AD-036 – undefined mechanism of action [6] Atomoxetine/mineralocorticoid receptor antagonist (atomoxetine/antimineralocorticoid; AD-113) – combination of atomoxetine (norepinephrine reuptake inhibitor) and a mineralocorticoid receptor antagonist [7] Atomoxetine/trazodone (trazodone/atomoxetine; AD-504) – combination of atomoxetine (norepinephrine reuptake inhibitor) and trazodone (various actions/hypnotic) [8] BAY-2586116 – potassium channel blocker [9] CX-1739 – ampakine (AMPA receptor positive allosteric modulator) [10] Dronabinol low-dose (tetrahydrocannabinol; THC; PP-001) – cannabinoid CB1 and CB2 receptor agonist [11] Dronabinol/palmidrol (SCI-110; THX-OSA01; THX-RS01; THX-110; THX-TS01; THC/PEA) – combination of dronabinol (THC; cannabinoid receptor agonist) and palmidrol (palmitoylethanolamine (PEA); various actions) [12] Lorundrostat (MLS-101; MT-4129) – aldosterone synthase (CYP11B2) inhibitor [13] Phentermine/topiramate (Qnexa; Qsiva; Qsymia; topiramate/phentermine; VI-0521) – combination of phentermine (norepinephrine releasing agent) and topiramate (various actions) [14] Research programme: Sleep disordered breathing therapeutics - Shinogi-Apnimed Sleep Science – undefined mechanisms of action [15] SASS-001 – purinergic P2X3 receptor antagonist [16] Sivopixant (S-600918) – purinergic P2X3 receptor antagonist [17] Sulthiame (SASS-002; sulthiame; Sultia; sultiame) – carbonic anhydrase inhibitor [18] [19] Trazodone/viloxazine (AD-816; viloxazine/trazodone) – combination of trazodone (various actions/hypnotic) and viloxazine (norepinephrine reuptake inhibitor) [20]
== Regulatory compliance == The European Commission has published harmonized rules on supplement products to assure consumers have minimal health risks from using dietary supplements and are not misled by advertising. In the United States and Canada, dietary supplements are considered a subset of foods, and are regulated accordingly. The U.S. Food and Drug Administration (FDA) monitors supplement products for accuracy in advertising and labeling. Dietary supplements are regulated by the FDA as food products subject to compliance with current Good Manufacturing Practices (CGMP) and labeling with science-based ingredient descriptions and advertising. When finding CGMP or advertising violations, FDA warning letters are used to notify manufacturers of impending enforcement action, including search and seizure, injunction, and financial penalties. Examples between 2016 and 2018 of CGMP and advertising violations by dietary supplement manufacturers included several with illegal compositions or advertising of vitamins and minerals. The U.S. Federal Trade Commission, which litigates against deceptive advertising in marketed products, established a consumer center to assist reports of false health claims in product advertising for dietary supplements. In 2017, the FTC successfully sued nine manufacturers for deceptive advertising of dietary supplements.
In October 2011, a Bowery Historic District was registered with the New York State Register of Historic Places and therefore was automatically nominated for listing on the National Register of Historic Places. A grassroots community organization named Bowery Alliance of Neighbors (BAN) in association with the community-based housing organization called the Two Bridges Neighborhood Council led the effort for creation of the historic district. The designation means that property owners will have financial incentives to restore rather than demolish old buildings on the Bowery. BAN was recognized for its preservation efforts with a Village Award from the Greenwich Village Society for Historic Preservation in 2013. The historic district runs from Chatham Square to Astor Place on both sides of the Bowery.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.